Bayer, Johnson & Johnson's heart drug Xarelto fails trial to widen use

Study data published in the NEJM reveal that Bayer and Johnson & Johnson's cardiovascular drug Xarelto did not reduce the rate of blood clots in certain high-risk patients, as reported Channel News Asia Sunday.

In the Mariner study, the investigators examined the effects of the drug in patients who were previously hospitalised for conditions associated with a higher risk of venous thromboembolism.

A Bayer spokesman said the results, which were also unveiled at the European Society of Cardiology annual congress, did not alter its peak sales estimate for Xarelto.

The German drugmaker posted 3.3 billion euros in revenue for the therapy last year.

 --------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.